RxDoctor Payments Data

Anil Sharma, MD

Psychiatry · Inglewood, CANPI 1447328109

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 57.2% of the total. Reporting peaked in 2022 at $404 and has fallen 86.7% since, to $54 in 2025.

$870in general payments, 2019–2025

Across 31 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$497
  • Alkermes, Inc.$216
  • Indivior Inc.$54
  • E.r. Squibb & Sons, L.L.C.$32
  • DJO, LLC$22
  • Lundbeck LLC$20
  • plus $29 from 2 others
$947,126in research payments, 2019–2025

Across 168 payments — averaging $5637.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Hoffmann-la Roche Limited$311K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$286K
  • Avanir Pharmaceuticals, Inc.$66K
  • Boehringer Ingelheim$51K
  • GRT US Holding, Inc.$50K
  • AbbVie$46K
  • plus $136K from 10 others

What the payments were for

  • Food & beverage$870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Medicare billing

Part B allowed, 2024
$62,309
Medicare patients
148
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate76$591,681
Clozapine85$4,025
Olanzapine OdtOlanzapine24$1,585
Divalproex Sodium37$1,519
Mirtazapine27$435
Quetiapine Fumarate26$311
Olanzapine18$220
Losartan Potassium11$188
Trazodone Hcl20$154
Aripiprazole15$152
Atorvastatin Calcium12$147

Paid to pharmacies, not to this prescriber.

Other psychiatry in Inglewood

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →